Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relugolix - Myovant/Takeda

Drug Profile

Relugolix - Myovant/Takeda

Alternative Names: ORGOVYX; Relumina; RVT 601; TAK-385

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Developer ASKA Pharmaceutical; Myovant Sciences; Takeda; Takeda Oncology
  • Class Analgesics; Antineoplastics; Fluorobenzenes; Ketones; Pyridazines; Pyrimidines; Small molecules; Thiophenes; Urea compounds
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Registered Uterine leiomyoma
  • Phase III Endometriosis
  • Phase II Pain
  • No development reported Solid tumours

Most Recent Events

  • 10 Sep 2021 Efficacy data from a phase III trial in Prostrate cancer presented at the 116th Annual Meeting of the American Urological Association (AUA-2021)
  • 04 Jun 2021 Updated efficacy and adverse events data from the phase III HERO trial in Prostrate cancer presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
  • 31 May 2021 Myovant Sciences completes the phase III SPIRIT 2 trial for Pain (Combination Therapy) in USA, Australia, Canada, Czech Republic, Georgia, Italy, New Zealand, Poland, Sweden, the UK, Brazil, Chile, Romania (NCT03204331)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top